The time course of plasma drug levels and urinary recovery for two lipopeptide antifungal antibiotics, L-671,329 and cilofungin, were measured in male rhesus monkeys (Macaca mulatta) and in female DBA/2 mice. The antibiotics were administered intravenously at 10 mg/kg of body weight in phosphate-buffered saline-26% polyethylene glycol for the rhesus monkeys and in 5% dimethyl sulfoxide for the mice. Plasma and urine drug concentrations were determined by high-pressure liquid chromatography and/or a microbiological assay versus AspergiUlus niger, and pharmacokinetic parameters were determined for both species. In each of the two rhesus crossover tests as well as in the mouse studies, the pharmacokinetics of the two compounds were similar; however, a marked difference was evident between species. The half-lives of L-671,329 and cilofungin in plasma were 39 and 34 min in the mice and averaged 1.8 and 2 h in the rhesus monkeys, respectively. In mice and rhesus monkeys, urinary recovery was <4% for both compounds.
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In the search for new therapeutic agents, animal models of disease states have been an indispensable tool for the prediction of efficacy in humans. For any number of reasons, a therapeutic advantage of one agent over another demonstrated in an animal model may not translate analogously to humans. Thus, it behooves an investigator to be critical of the models he relies on and to develop additional experimental procedures to confirm his predictions. It is customary in our laboratory, for example, to explore any species-specific pharmacokinetic properties of a compound of interest. A comparison in rodents versus primates provides some of the additional parameters necessary for projecting success or failure in humans.
In this study, species-specific pharmacokinetics of two recently reported, structurally similar ( Fig. la and b) lipopeptide antifungal antibiotics, L-671,329 and cilofungin (LY-121019, L-646,991), are presented. These agents have fungicidal, narrow-spectrum activity against Candida and Aspergillus spp. (1, 5, 6) , and L-671,329 has also been shown to have activity against Pneumocystis cannii (9, 10). They both have the potential for improved efficacy and tolerance over existing therapy.
MATERUILS AND METHODS
Mice. Female DBA/2 mice weighing 20 + 2 g were used in these studies. The mice were housed and fed in accordance with National Institutes of Health guidelines (2) .
Rhesus monkeys. Two male rhesus monkeys (Macaca mulatta) weighing 4.8 kg were used in these studies. They were also housed and fed in accordance with National Institutes of Health guidelines (2) .
Drugs. L-671,329 and cilofungin were prepared in our laboratory by published methods (4, 11). They were diluted in 5% dimethyl sulfoxide to 1.0 mg/ml or phosphate-buffered saline-26% polyethylene glycol (molecular weight, 300) to 10 mg/ml. Samples were kept on ice at 0°C and administered the same day.
HPLC conditions. Conditions for high-pressure liquid chromatography (HPLC) Sample preparation. Samples of whole blood or urine, unknowns, and controls spiked with known concentrations were diluted in 3 volumes of 50% methanol-50 mM potassium phosphate buffer (pH 6.5). This treatment was suitable for the microbiological assay. Further treatment for HPLC (blood only) involved dilution of the above-described mixture in acetonitrile (1:1; final dilution, 1:8), 1 h of incubation at 0°C, and centrifugation at 10,000 x g.
Pharmacokinetics. Three mice were used per time point; each mouse was given 200 ,ug of drug intravenously (i.v.) in 0.2 ml of 5% dimethyl sulfoxide. Blood was collected by heart puncture with heparinized syringes at 1, 5, 15, 30, 60, 90, 120, and 180 min. Blood from three mice was pooled prior to being processed. Urine was collected from a group of five mice over a 3-h period in a metabolism cage, allowing the separation of urine and feces.
Two male rhesus monkeys were anesthetized with ketamine hydrochloride (Ketaset; 100 mg/ml) given intramuscularly at 10 mg/kg of body weight as needed to maintain anaesthesia throughout the experiment. To promote urine flow and allow the measurement of glomerular filtration rates, we started an i.v. infusion of 5% mannitol-saline containing 0.5 ,Ci of 51Cr-EDTA per ml and maintained it at 1.0 ml/min for the duration of the procedure. The monkeys were then each given 1 uCi of5Cr-EDTA and 10 mg of L-671,329 or cilofungin per kg of body weight in 4.8 ml of phosphate-buffered saline-26% polyethylene glycol by i.v. (Tables 1 and 2 ) established for L-671,329 and cilofungin demonstrated the equivalence of these two lipopeptide compounds. The CLs were similar, even in the two monkeys, i.e., 12.8 (L-671,329) versus 16.8 (cilofungin) ml/min/kg in one monkey and 4.9 (L-671,329) versus 4.8 (cilofungin) ml/min/kg in the other.
Other parameters, i.e., VsS, tl/2P, AUCO3.5, and AUCO,, all showed the equality of these two compounds. Urinary recovery, extrapolated to infinity, was uniformly low (<4%) in both the rhesus monkeys and the mice, indicating nonrenal clearance for these compounds in both species.
In mice, L-671,329 and cilofungin were cleared rapidly in the initial distribution phase and then slowly cleared from the central compartment (Fig. 2) . The pharmacokinetic parameters found for the mice also showed that these two compounds are very similar in the way that they are processed by this species.
DISCUSSION
The kinetics of elimination of cilofungin in rabbits have been shown to be nonlinear by Lee et al. (7) and Walsh et al. (14), and the elimination pathway is predominantly hepatic (7) . The low urinary recovery (CL > > CLR) observed in our studies of mice and rhesus monkeys suggests that the disposition of both compounds in these species is analogous to the rabbit pathway for cilofungin. This analogy probably extends to the nonlinear phenomenon as well. This hypothesis, of course, is impossible to demonstrate in single-dose, single-subject experiments.
In the studies cited above, the observed deviation from linearity occurred at doses far in excess of the dose used in our studies of L-671,329 and cilofungin. While this fact does not guarantee that each of the elimination processes in our animals was linear, the fits to the two-compartment model, the derivation of which is based on linear first-order transitions, were quite acceptable. Nevertheless, it is important to note that, in the absence of an established physical model, this mathematical model is only an approximation useful for specific comparisons only.
While a two-animal study clearly cannot represent a general model for primate pharmacokinetics, certain features of the kinetic picture are worth highlighting. Trailing plasma drug levels in the rhesus monkey studies (Fig. 3a and  b ) demonstrated low-level persistence for both compounds despite what appeared to be a very rapid overall clearance rate. It is noteworthy that the clearance of these antibiotics from the mice was very close to that from one of the rhesus monkeys (no. 14338) and slower than that from the other rhesus monkey (no. 14156). Given the usual relationship between CL and body weight [log CL = (0.662. log body weight) + 0.648] (12) which results in a 20-g mouse clearing a drug approximately sixfold faster than a 5-kg monkey on a milliliter-per-minute-per-kilogram basis, the clearance of these compounds from the mice was unusually slow.
On the basis of in vitro susceptibilities (1), inhibitory levels of these compounds are achievable in the circulation. The pharmacokinetic parameters in the mice and rhesus monkeys clearly demonstrated the similarity of the two compounds evaluated in this study. Given the unusually favorable elimination kinetics in mice, our in vivo efficacy model, it will be a challenge to propose an efficacious dosage regimen in higher species, e.g., humans. Some degree of scaling will be necessary. More knowledge is needed to identify which pharmacokinetic parameter correlates best with therapeutic efficacy. One aspect that might be considered is the apparently slow fungicidal mode of action (6) 
